← Back to Screener
Pacific Biosciences of California, Inc. (PACB)
Price$1.58
Value ScoreD
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-36.67%
Price vs S&P 500 (4W)-11.85%
VGM Score46.23
Market Capitalization$462.80M
All Metrics
Book Value / Share (Quarterly)$0.01
P/TBV (Annual)4.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.64%
Cash Flow / Share (Quarterly)$-0.39
Price vs S&P 500 (YTD)-31.25%
Gross Margin (TTM)40.31%
Net Profit Margin (TTM)-80.34%
EPS (TTM)$-0.43
10-Day Avg Trading Volume6.09M
EPS Excl Extra (TTM)$-0.43
Revenue Growth (5Y)15.19%
EPS (Annual)$-1.82
ROI (Annual)-83.96%
Gross Margin (Annual)31.22%
Net Profit Margin (5Y Avg)-215.87%
Cash / Share (Quarterly)$0.89
Revenue Growth QoQ (YoY)0.07%
ROA (Last FY)-69.68%
Revenue Growth TTM (YoY)5.04%
EBITD / Share (TTM)$-0.43
ROE (5Y Avg)-2079.63%
Operating Margin (TTM)-83.29%
Cash Flow / Share (Annual)$-0.39
P/B Ratio195.60x
P/B Ratio (Quarterly)168.49x
Net Income / Employee (Annual)$-1,126,500
EV / Revenue (TTM)5.19x
Net Interest Coverage (TTM)-77.52x
ROA (TTM)-16.10%
EV / EBITDA (TTM)24.41x
EPS Incl Extra (Annual)$-1.82
Current Ratio (Annual)5.15x
Quick Ratio (Quarterly)4.67x
3-Month Avg Trading Volume6.42M
52-Week Price Return43.27%
Revenue / Employee (TTM)$330,000
Tangible BV / Share (Quarterly)$0.07
P/S Ratio (Annual)2.89x
Asset Turnover (Annual)0.20x
52-Week High$2.73
Operating Margin (5Y Avg)-232.44%
EPS Excl Extra (Annual)$-1.82
CapEx CAGR (5Y)49.30%
26-Week Price Return-20.74%
Quick Ratio (Annual)4.32x
13-Week Price Return-16.29%
Total Debt / Equity (Annual)120.65x
Current Ratio (Quarterly)5.65x
Enterprise Value$830.94M
Revenue / Share Growth (5Y)3.42%
Asset Turnover (TTM)0.20x
Book Value / Share Growth (5Y)-60.07%
Revenue / Employee (Annual)$329,900
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-341.28%
Cash / Share (Annual)$0.93
3-Month Return Std Dev80.83%
Gross Margin (5Y Avg)34.06%
Net Income / Employee (TTM)$-265,100
ROE (Last FY)-10214.54%
Net Interest Coverage (Annual)-17.37x
EPS Basic Excl Extra (Annual)$-1.82
Receivables Turnover (TTM)5.25x
Total Debt / Equity (Quarterly)272.23x
EPS Incl Extra (TTM)$-0.43
Receivables Turnover (Annual)5.08x
ROI (TTM)-19.14%
P/S Ratio (TTM)2.89x
Pretax Margin (5Y Avg)-231.29%
Revenue / Share (Annual)$0.53
Tangible BV / Share (Annual)$0.40
Price vs S&P 500 (52W)15.06%
Year-to-Date Return-20.32%
5-Day Price Return22.13%
EPS Normalized (Annual)$-1.82
ROA (5Y Avg)-27.73%
Net Profit Margin (Annual)-341.47%
Month-to-Date Return-6.29%
Cash Flow / Share (TTM)$-1.22
EBITD / Share (Annual)$-1.83
Operating Margin (Annual)-346.15%
LT Debt / Equity (Annual)120.65x
ROI (5Y Avg)-32.46%
LT Debt / Equity (Quarterly)272.23x
EPS Basic Excl Extra (TTM)$-0.43
P/TBV (Quarterly)19.27x
P/B Ratio (Annual)105.55x
Inventory Turnover (TTM)1.82x
Pretax Margin (TTM)-79.84%
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)-26.04%
Beta2.36x
P/FCF (Annual)25.07x
Revenue / Share (TTM)$0.52
ROE (TTM)-488.45%
52-Week Low$0.96
vGradeD
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.12est. -0.14
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.73
3.81
3.75
3.75
Industry Peers — Lab Analytical Instruments(24)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PACBPacific Biosciences of California, Inc. | D | C | C | $1.58 |
| AAgilent Technologies Inc. | C | C | B | $135.98 |
| WATWaters Corp | D | C | B | $378.16 |
| ILMNIllumina Inc | D | D | A | $164.40 |
| MTDMettler-Toledo International | D | C | C | $1183.57 |
| RVTYRevvity, Inc. | C | D | B | $100.52 |
| BRKRBruker Corporation | D | D | A | $58.44 |
| BIOBio-Rad Laboratories, Inc.Class A | C | F | B | $305.46 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | F | B | $304.15 |
| AVTRAvantor, Inc. | B | D | C | $9.19 |
| TXG10x Genomics, Inc. Class A Common Stock | D | C | A | $29.59 |
About
Pacific Biosciences develops and manufactures DNA sequencing platforms that enable genetic analysis for research and clinical applications. The company's integrated technology helps scientists and clinical researchers identify and resolve complex genetic problems. Revenue is generated primarily from the Americas, with significant contributions from Europe, the Middle East, Africa, and Asia-Pacific.